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Abstract 
African swine fever is a hemorrhagic disease of domestic pigs caused by African swine 
fever virus (ASFV), a double-stranded DNA virus and the only member of the family Asfarviridae. 
The structure of this multilayer virion contains more than 34 proteins including the protein p72 
which is the major capsid protein. A single conformational neutralizing epitope has been identified 
on p72, but information on the other antigenic regions (epitopes) is lacking. The objective of this 
study was to identify p72 epitopes using polyclonal swine sera and a panel of monoclonal 
antibodies with the ultimate goal being the development of a blocking ELISA assay for the 
detection of anti-ASFV antibodies. The segment of the p72 protein from amino acids 1 to 345 was 
divided into five overlapping fragments which were then commercially synthesized. These 
fragments were cloned into the pHUE expression vector and transformed into Escherichia coli 
competent cells. The recombinant proteins were expressed in vitro, purified, and used as antigens 
in indirect ELISAs and western blots to test monoclonal antibodies and polyclonal swine sera. The 
monoclonal antibodies were produced against the p72 protein based on the ASFV Georgia/07 
strain. The polyclonal sera were obtained from pigs immunized with a defective alphavirus 
replicon particle, RP-sHA-p72, expressing a recombinant protein composed of the extracellular 
domain of the ASFV HA protein together with the whole p72 protein. The polyclonal sera reacted 
to p72 in two distinct regions: between amino acids 1 and 83 and between amino acids 250 and 
280. The anti-p72 reactive monoclonal antibodies reacted with p72 in three regions: between 
amino acids 100 and 171, amino acids 180 and 250, and amino acids 280 and 345. Fine mapping 
with oligopeptides allowed for the identification of six different linear epitopes. Among the 
monoclonal antibodies selected for blocking assay development, two have been shown to be 
promising candidates for further evaluation using sera from ASFV-infected pigs.  
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Chapter 1 - African Swine Fever Virus Literature Review 
 African swine fever 
African swine fever (ASF) is a highly contagious and lethal viral disease of swine that 
has had a significant socioeconomic impact in the developed and developing world, making it a 
global animal health priority (Agüero et al., 2003; Sanchez-Vizcaino & Neira 2012). Although 
the disease is not currently present in the United States (OIE, 2013), it is crucial that the United 
States is able to detect the presence of ASFV so that the negative impacts that have occurred 
elsewhere during outbreaks of ASFV are minimized should such an outbreak occur in this 
country (Oura, Edwards, & Batten, 2013). Currently, however, there are no diagnostic assays 
available in the United States to test for the presence of ASFV. A contributing factor for the lack 
of diagnostic assays to test for the virus is the limited information available regarding the 
antigenic binding sites, or epitopes, on the major viral proteins. Determining the locations on 
these proteins to which antibodies are able to bind, a process known as epitope mapping, would 
facilitate the development of serological diagnostic assays that could be used to test for the 
presence of this significant swine pathogen should it be imported into the United States.  
African swine fever virus (ASFV), the causative agent of ASF, is a large icosahedral 
DNA virus of about 193 kilobase pairs (kbp) with a conserved central region of approximately 
125 kilobases (kb) and variable ends (Dixon et al., 2005). The disease can occur in various 
forms, ranging from highly lethal to subclinical infections, resulting in up to 100% morbidity in 
naïve pigs of all breeds and ages. Mortality rates vary between 0% and 100% depending on the 
viral isolate; health, age, and other factors affecting the host; the dose; and the route of exposure 
to the virus (Costard, Mur, Lubroth, Sanchez-Vizcaino, & Pfeiffer, 2013).  
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ASF affects members of the Suidae family with no evidence suggesting zoonosis. It 
infects a range of domestic and wild suids and, depending on the species, can cause disease or 
result in an asymptomatic carrier state in the animal (Costard et al., 2013). Species affected 
include the domestic pig (Sus scrofa domesticus), Eurasian wild boar (Sus scrofa), warthogs 
(Phacochoerus aethiopicus), bush pigs (Potamochoerus porcus), and giant forest hogs 
(Hylochoerus meinertzhageni) (Costard et al., 2013; Kleiboeker, 2008). Warthogs and bush pigs 
are known to be wildlife reservoirs for the virus in Africa. Additionally, the argasid soft tick of 
the genus Ornithodoros can serve as vectors for transmission of the virus in Africa (Anderson, 
Hutchings, Mukarati, & Wilkinson, 1998; Burrage, 2013; Penrith, Vosloo, Jori, & Bastos, 2013).  
 ASFV was first documented in domesticated swine in Kenya in 1921. Sanchez-Botija 
describes evidence for the first known cases of ASFV infection outside of Africa. This occurred 
in Portugal in 1957 as a result of waste from airline flights being fed to pigs in areas with close 
proximity to the Lisbon airport. This outbreak was successfully eradicated but soon after more 
outbreaks occurred in additional European countries. Since the 1960s, outbreaks have occurred 
in Italy, Spain, Malta, Belgium, and the Netherlands (as cited in Costard et al., 2009; Oura, 
Powell, Anderson, & Parkhouse, 1998). In the 1970s, the virus then spread to South America and 
the Caribbean but was eradicated from these areas by the death or depopulation of infected pigs. 
In 2007, ASFV was introduced into the Caucasus region via the Republic of Georgia and spread 
into Eastern Europe where it has become endemic (Costard et al., 2013). Since that time, the 
disease has spread rapidly among the domestic and wild pig populations causing widespread 
disease throughout this vast region and extending from Russia to the edges of Eastern Europe. 
Outbreaks continue to be reported periodically outside of the continent of Africa, causing great 
economic losses in the affected countries. Eradication has been achieved in most of these cases, 
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although it remains endemic in Sardinia, Italy, and most of sub-Saharan Africa (Sánchez-
Vizcaíno & Neira , 2012). Currently ASFV is present in the African countries of Togo, Kenya, 
Burundi, Mali and South Africa and outside of Africa in Sardinia, Poland, Lithuania, Russia, and 
the Ukraine (Arzt, White, Thomsen, & Brown, 2010; OIE, 2013).  
Increases in pig populations in Eastern Asia as well as continued increases in trade 
activity have led to concerns that ASFV could spread further across Europe and Asia (Costard et 
al., 2013). Spread of the virus across Eurasia and into Europe could allow the virus to be carried 
from Europe into North America via existing intercontinental commerce. The United States has 
been one of the top world pork import and export countries, and it is crucial that the country 
protects its own swine industry from this devastating viral disease. Because the introduction of 
ASF into the United States would have an enormous economic impact similar to what has 
occurred in other countries, the potential of introducing ASF into the country is a risk that needs 
to be mitigated (Center for Food Security and Public Health, College of Veterinary Medicine, 
Iowa State University, 2015).  
Based on the impact that ASF would have on pork production and trade, as well as the 
costs of eradicating the disease should the virus appear in the United States, it has been estimated 
that the net benefit of preventing the introduction of ASF into the country is approximately $4.5 
billion (Costard et al., 2009). Since there is no effective vaccine or preventative measures 
available to combat ASF, the current outbreaks in Eastern Europe have created interest in 
developing rapid and specific diagnostic assays for surveillance of the virus (Dixon, Chapman, 
Netherton, & Upton, 2013; Gallardo et al., 2015; Oganesyan et al., 2013). 
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 Clinical signs 
Pigs infected with ASF exhibit numerous clinical signs as well as gross pathology that are 
similar to those observed in animals suffering from other diseases. These diseases include 
classical swine fever (CSF), salmonellosis, erysipelas, porcine dermatitis and nephropathy 
syndrome (PDNS), and porcine reproductive and respiratory syndrome (PRRS). As a result, it 
can be difficult to distinguish ASF from these other diseases by either clinical or post-mortem 
examination (King et al., 2003; OIE, 2012; Oura, Edwards, & Batten, 2013; United States 
Animal and Plant Health Inspection Service, 1998). Therefore, the only way to differentiate 
infection with ASFV from other swine diseases is through diagnostic tests. 
The clinical presentation of ASFV varies from hyperacute, with almost 100% mortality 
after 4 to 7 days post-infection (dpi), to chronic disease, with most animals surviving and 
becoming carriers of the disease. Infection with different viral isolates results in these varying 
degrees of illness (Blome, Gabriel, & Beer, 2013; Martínez-López et al., 2015). Hyperacute and 
acute disease are the most severe forms of ASF. Acute disease is characterized by a 3- to 5-day 
incubation period followed by a high fever and rapid death within 5 to 10 days from initial 
infection. Hyperacute disease has a more rapid onset when compared to acute disease. The 
chronic form is more insidious; clinical manifestations of disease develop more slowly and 
mortality rates are not as high but hallmarks of the disease ultimately appear. Subacute disease 
presents as an intermediate level of illness between what is seen in the hyperacute or acute forms 
and the chronic form. Similarly, the time required for clinical manifestations to develop is also 
intermediate in nature for subacute disease. The subacute and chronic forms are more difficult to 
recognize when compared to acute or hyperacute disease since the symptoms are less severe and 
mortality rates are lower. Furthermore, if subacute or chronic forms of ASF occur in an area 
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where the virus has never been detected, the lack of experience of farmers and veterinarians with 
ASFV infection can make this disease more difficult for them to detect. These different forms of 
ASF are seen with varying frequency in the regions where the virus has been detected. For 
example, within the continent of Africa, acute ASF is seen more frequently than the less severe 
forms of infection. In recent outbreaks elsewhere, the most predominant forms of ASF have been 
the subacute or chronic forms of the disease. (Kleiboeker, 2008; Oura et al., 2013; United States 
Animal and Plant Health Inspection Service, 1998).  
Infection can produce a wide range of symptoms including fever, anorexia, cyanosis of 
the skin, vomiting, diarrhea, tachycardia, tachypnea, arthritis, incoordination, and death. 
Abortion may also occur in pregnant sows (Kleiboeker, 2008; OIE, 2012). Extensive 
hemorrhages occur predominately in the lymph nodes, kidneys, and heart. Edema, pericarditis, 
splenomegaly, and hyperemia of the intestines are also observed (Galindo-Cardiel et al., 2013). 
The extent and nature of the symptoms and gross lesions will vary depending upon the virulence 
of the strain, host factors, and the course of the disease (Blome et al., 2013; Gómez-Villamandos, 
Bautista, Sánchez-Cordón, & Carrasco, 2013).  
ASFV isolates have shown a preference for infecting cells of the mononuclear phagocytic 
system. The virus replicates primarily in monocytes and lymphocytes and attacks other myeloid 
lineage cells as well, including leukocytes and dendritic cells. These antigen presenting cells 
(APCs) have critical roles in the immune system (Blome et al., 2013; Muñoz-Moreno, Galindo, 
Cuesta-Geijo, Barrado-Gil, & Alonso, 2015; Takamatsu et al., 2013). Infection with more 
virulent isolates of the virus results in increased viral replication and accumulation of the virus in 
tissue compared to less virulent isolates. High levels of virus have been detected in the spleen, 
lymph nodes, liver, kidney, lungs, and tonsils. Specific macrophage types demonstrated to be 
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infected with ASFV include red pulp macrophages, extrafollicular macrophages of gastrohepatic 
and submandibular lymph nodes, Kupffer cells in the liver, pulmonary intravascular 
macrophages, and extrafollicular macrophages of the tonsils (Oura et al., 1998). 
In Europe, wild boar and feral pigs have been shown to be as susceptible as domestic pigs 
to ASFV infection (Correia, Ventura, & Parkhouse, 2013; Galindo-Cardiel et al., 2013; Jori & 
Bastos, 2009). Some animals, such as warthogs and bush pigs, become infected but are 
asymptomatic; they do not develop the typical clinical signs and symptoms (Burrage, 2013; 
Kleiboeker, 2008). High rates of morbidity and mortality, along with rapid spread of the virus, 
are usually seen when ASFV is introduced into a geographical region or pig population 
previously devoid of the virus. Conversely, morbidity and mortality rates have been reported to 
be lower in regions where ASFV is endemic (Costard et al., 2013).  
 Transmission 
ASF spreads rapidly in pig populations through direct animal-to-animal transmission via 
the oronasal route or indirect contact via fomites including vehicles, feed, and equipment. 
Additionally, the argasid soft ticks of the genus Ornithodoros can serve as vectors for 
transmission of ASFV, creating the infection cycle that maintains the virus in Africa via 
O. moubata, although infection with ASFV can also be fatal for these ticks (Burrage, 2013; Hess, 
Endris, Lousa, & Caiado, 1989; Kleiboeker & Scoles, 2001). Animals who exhibit subclinical 
disease, are chronically infected, or have recovered from infection are likely to contribute to the 
persistence of the virus in areas where it is endemic. These animals may also contribute to 
sporadic outbreaks and spread of ASFV into areas where it had not previously existed. This is 
thought to be due to the fact that animals can remain infected for several weeks and, during that 
time, are able to spread the virus to other pigs through direct or indirect contact (Costard et al., 
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2013). The virus is shed from infected animals and can be found in all excretions and secretions. 
Once shed, the virus can survive outside of the host for several days which is another 
contributing factor for the spread of disease (Montgomery, 1921; United States Animal and Plant 
Health Inspection Service, 1998).  
Pig production plays a major role in providing food security within the continent of 
Africa and throughout the world (Thomson, 1985). Different types of farms such as commercial 
pig units, small and semi-commercial units, and partially to fully free-range farms have 
considerably different biosecurity measures. This range in biosecurity is an important 
contributing factor to the spread of ASF and other diseases (Mokoele et al., 2015). Another 
factor contributing to the spread of ASFV is the feeding of uncooked garbage (swill) to pigs. 
ASFV remains infectious for long periods of time in uncooked pork products, such as blood and 
tissue. For example, ASFV has been shown to survive in natural sausage casings for 97 days 
(Arzt et al., 2010; Costard et al., 2009; United States Animal and Plant Health Inspection 
Service, 1998; Wieringa-Jelsma et al., 2011). The ability of the virus to survive in pork products 
for such a long period of time facilitates introduction of the virus into new areas. Additionally, 
transmission of aerosolized virus is suggested to occur over short distances, depending on the 
time the particles remain in the air and biological decay (de Carvalho Ferreira, Weesendorp, 
Quak, Stegeman, & Loeffen, 2013; Gallardo et al., 2011). 
It has been shown that Ornithodoros ticks infected with ASFV are able to carry the virus 
for 6 months or longer and it may persist for years. When the ticks are present in the 
environment where infected animals had previously existed, these ticks could infect healthy 
animals when swine are reintroduced to the farm following culling of the herd (Hess et al., 1989; 
Plowright, Parker, & Peirce, 1969; United States Animal and Plant Health Inspection Service, 
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1998). Ornithodoros erraticus was first identified as a vector and reservoir for ASFV in Spain by 
Sanchez-Botija in the 1960s. Subsequently Plowright et al. showed the importance of other 
Ornithodoros species, including the Ornithodoros moubata complex, in Africa (as cited in 
Burrage, 2013; Costard et al., 2009, 2013; Rennie, Wilkinson, & Mellor, 2001). There are tick 
species present in North America (O. coriaceus, O. turicata, and O. parkeri) that have been 
experimentally shown to be able to carry ASFV (Costard et al., 2009; Sanchez-Vizcaino & 
Neira, 2012). This is concerning because if ASFV was to appear in North America, these ticks 
could serve as a vector for spread of the virus among uninfected animals. 
Infection of the tick helps to maintain the virus in Africa by the way of the naturally 
occurring cycle between warthog, bushpig, and tick (Burrage, 2013; Costard et al., 2013). When 
an infected tick bites a previously uninfected warthog, the virus replicates in the animal and a 
low level of viremia develops. Although low, this level of viremia is sufficient to infect other 
ticks that in turn feed on the hog. Domestic pigs are then infected when they are bit by the 
infected ticks (Burrage, 2013). Warthogs, thought to be the original vertebrate host of ASF, are 
widely distributed throughout Africa. There are a multitude of factors making the warthog the 
most important vertebrate reservoir for ASFV; living in burrows that are also inhabited by 
Ornithodoros ticks, the behavior of young animals, and both direct and indirect contact with 
domestic pigs are a few of these factors (Costard et al., 2013).  
Transstadial, transovarial, and sexual transmission of ASFV has been demonstrated in 
these ticks, although these factors are dependent upon the species of tick and the strain of the 
virus (Mellor & Wilkinson, 1985). The Ornithodoros ticks are long lived which contributes to 
the ability of the tick colonies to maintain ASFV for several years. Transovarial transmission of 
ASFV has been shown to occur from ticks of the O. moubata complex, allowing for the survival 
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of the virus within the tick population in the absence of infected animals. ASFV has also been 
shown to replicate within tick eggs. The likelihood that ASFV will be maintained within the tick 
population increases when ticks have a regular supply of blood meals; however, if not 
reintroduced to the virus, the ticks will eventually clear the infection (Plowright, Perry, & Greig, 
1974; Rennie et al., 2001). It is important to note that although the Ornithodoros tick can serve 
as a vector for ASFV, the tick is not a required intermediate vector for the transmission of 
ASFV. Viral spread occurs more commonly via other mechanisms of infection such as direct 
contact between infected and uninfected animals 
There is international interest in preventing this virus from entering other countries. Poor 
biosecurity, together with the extensive commercial trade, keeps ASFV-free countries such as the 
United States at a constant risk of having the disease introduced (Agüero et al., 2003). A large 
population of pigs is a risk factor contributing to the probability that a country may become 
infected with ASFV (Penrith et al., 2013). Because of the presence of potential tick vectors and 
feral pig populations in North America along with the fact that the United States is one of the top 
world pork producers, proper biosecurity practices are vital for the prevention of the virus 
entering the country.  
 Control 
ASFV is a notifiable disease; if the virus is suspected, it should be reported immediately. 
A quick response and prevention of further infection is key for containing any outbreaks in 
ASFV-free regions (OIE, 2012). In countries where ASFV is endemic, successful eradication 
programs are based on the diagnosis of ASFV, the culling of pigs that are infected or have 
possibly been in contact with the disease, safe carcass disposal, sanitation, disinfection, animal 
movement controls and quarantines, and the prevention of domestic pig contact with wild pigs 
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and infected ticks. Eradication is difficult and can take decades to accomplish due to the presence 
of reservoirs for the virus in the wild. This process is even more difficult when tick vectors are 
present. Furthermore, eradication efforts are expensive due to costs associated with proper 
disposal of carcasses and those costs involved with repopulating a farm (Cubillos et al., 2013; 
Scott, 1965). 
Currently, there is no effective vaccine available with which to combat ASFV; there is 
ongoing research for vaccine development (Bastos et al., 2003; Zsak, Onisk, Afonso, & Rock, 
1993).  Experimentally, classically attenuated vaccines using the non-virulent Portuguese isolate 
OURT88/3 and virulent isolate OURT88/1 have been shown to be efficient at controlling 
homologous challenge but were limited against heterologous challenge (King et al., 2011; 
Lacasta et al., 2015; Oura, Denyer, Takamatsu, & Parkhouse, 2005). It has been suggested that 
the outbreaks in the Iberian Peninsula between 1960 and 1995 were a consequence of the use of 
live attenuated vaccines (Costard et al., 2013). Although this type of vaccine has been 
demonstrated to induce a protective immune response, the use of live attenuated vaccines, 
especially in regions where the virus is not present, has been limited due to their infectious 
nature (Lacasta et al., 2015).  
As mentioned, ASF infection can be maintained in an area through the activity of 
Ornithodoros ticks. In areas where ticks played a key role in the establishment and maintenance 
of ASFV infections, the risk of infection decreased following the elimination of the tick 
population. Therefore, control measures for ASF need to include methods to eradicate ticks from 
environments, such as the use of acaricides (Costard et al., 2013).  
Decontamination of possible fomites and the premises where infected animals had been 
housed reduces the risk of spreading the virus to additional animals who have not been infected 
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with ASFV. Proper disinfection is crucial for the prevention of ASFV spread and can be 
achieved through a wide range of techniques. The virus is highly resistant in the environment and 
has been found to survive for 2 to 3 months under most environmental conditions. It has been 
found to survive for 3 months in ham, 6 months in bone marrow, and 18 months in blood meal. 
ASFV has also been shown to survive for 11 days in feces at room temperature and at least 
1 month in contaminated pig pens (Carillo, 2014; Food & Agriculture Organisation of the United 
Nations, n.d.).  ASFV is stable over a wide pH range from a pH of 4 to a pH of 10. Furthermore, 
many common disinfectants are ineffective against ASFV. Sodium hypochlorite (an oxidizing 
agent), a 1% citric acid solution, alkalis, iodine, and quaternary ammonium compounds have 
been reported to destroy the virus and are the disinfectants of choice for decontaminating ASFV 
(Krug, Larson, Eslami, & Rodriguez, 2012; Krug, Lee, Eslami, Larson, & Rodriguez, 2011; 
Shirai, Kanno, Tsuchiya, Mitsubayashi, & Seki, 2000). A few examples of these disinfectants 
include CaviCide® and VirkonTM S. CaviCide®, an alkali, is a non-corrosive cleaner that can be 
used as an effective disinfectant for ASFV. The alcohols in the compound break down the 
lipoprotein complexes and penetrate the cell membrane to cause irreversible damage to the inside 
of the cell (Crawford, Yu, Keegan, & Yu, 2000; Severs & Lamontagne, 2002). A 1% solution of 
VirkonTM S, an oxidizing agent, is recommended for cleaning and disinfecting swine units as 
well as agricultural equipment and instruments. This disinfectant has been proven effective, 
although it can be expensive and difficult to use on farms (Amass, Ragland, & Spicer, 2001; 
Herńndez, Martró, Matas, Martín, & Ausina, 2000).  
The United States Department of Agriculture (USDA) prohibits the import of live pigs 
and uncooked pork products from those regions infected with ASFV to prevent the introduction 
of ASF into the United States (United States Animal and Plant Health Inspection Service, 1998). 
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As another precaution, the feeding of uncooked garbage to pigs has also been prohibited in some 
countries (Scott, 1965). Unprocessed meat must be heated to a minimum of 70 ˚C for 30 minutes 
to inactivate ASFV; 30 minutes at 60 ˚C has been found sufficient for the inactivation of serum 
and body fluids (Center for Food Security and Public Health, College of Veterinary Medicine, 
Iowa State University, 2015). In a study by Wieringa-Jelsma et al., (2011) both sodium chloride 
salt and phosphate supplemented salt were also found to be capable of inactivating ASFV within 
48 hours.  
 African swine fever virus 
The causative agent of ASF is African swine fever virus (ASFV) which belongs to the 
genus Asfivirus and is the only member of the family Asfarviridae (Dixon et al., 2013). The 
Asfarviridae family is included in the nucleocytoplasmic large DNA virus (NCLDV) 
superfamily, order Megavirales. Members of NCLDV include Poxviridae, Iridoviridae, 
Ascoviridae, Phycodnaviridae, Mimiviridae, and Marseilleviridae. Poxviruses and asfarviruses 
infect vertebrate animals whereas mimiviruses, phycodnaviruses, and Marseilleviruses infect 
diverse unicellular eukaryotes. The NCLDVs share a common origin and undergo crucial parts 
of their replication within the cytoplasm of the infected cells (Colson et al., 2013). Most 
members of this group have an icosahedral morphology, with the exception of the Poxviridae 
family. Despite the different morphologies of ASFV and poxvirus, their genome structures are 
the same and they both have the ability to regulate their gene expression by temporal control of 
transcription (Rodríguez & Salas, 2013; Salas & Andrés, 2013). 
ASFV is a large enveloped virus that has an average diameter of approximately 200 nm 
(Kleiboeker, 2008). The viral genome of ASFV consists of a linear, double-stranded DNA 
molecule that ranges in length from 170 to 193 kilobase pairs (kbp) depending on the specific 
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viral isolate. The genome encodes for more than 150 polypeptides, at least 50 of which result in 
production of the structural proteins that comprise the different domains of the viral particle. 
High antigenicity has been shown in 14 of these polypeptides. Some of the viral genes code for 
the enzymes required for transcription and viral replication while others are involved in virus-
host interactions, such as permitting the virus to evade host cell defenses and altering host cell 
function to aid in the survival of the virus (Dixon et al., 2013; Epifano, Krijnse-Locker, Salas, 
Rodríguez, & Salas, 2006; Kollnberger, Gutierrez-Castañeda, Foster-Cuevas, Corteyn, & 
Parkhouse, 2002). There are many genes for which the function remains unknown although it has 
been suggested that many of these are involved with the ability of the virus to survive and grow 
in the tick (Burrage, 2013).  
The dense 80 nm virion core is composed of a nucleoid, which contains the viral genome, 
and the nucleoproteins p10 and pA104R. This core is enclosed by the core shell that contains 
several major components of the virus particle including p35, p15, p150, p37, p34, and p14 
(Andrés, Alejo, Salas, & Salas, 2002; Salas & Andrés, 2013). Surrounding the core are two lipid 
bilayers. These bilayers form the inner envelope and, outside of this envelope, is an icosahedral 
capsid (Cubillos et al., 2013). Constituents of the inner envelope include p54, p17, pE248R, and 
p12. The capsid structure is composed of p72, pE120R, and pB438L (Figure 1.1). The virus exits 
from the host cells by budding through the plasma membrane and, in this way, obtains an outer 
envelope which contains the proteins p24, CD2v, p30, and p12 (Paulino Gómez-Puertas et al., 
1998; Salas & Andrés, 2013).  
 Capsid protein p72 
The gene B646L codes for a protein with a molecular weight of 72 kDa that is expressed 
late in infection (Dixon et al., 2013; López-Otín, Freije, Parra, Méndez, & Viñuela, 1990; 
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Pitcher, Dixon, & Turner, 1992). This protein, p72, comprises about 32% of the total protein 
mass of the virion (Bastos et al., 2003). It is involved in virus attachment (Dixon et al., 2013) and 
is a major immunogen in natural infection (Tabares, Fernandez, Salvador-Temprano, Carnero, & 
Sanchez-Botija, 1981). In 1993, Zsak et al. (1993) identified that p72 contains a highly 
conserved neutralizing epitope. This epitope was shown to be conformational in a study by 
Borca and colleagues (1994). The correct folding and assembly of p72 in the virion requires a 
virus-encoded chaperone protein encoded by gene B602L. B602L prevents the capsid protein 
from aggregating before it is delivered onto the capsid shell. B602L and p72 then dissociate after 
folding but before the assembly of p72 into the virion (Cobbold, Windsor, & Wileman, 2001; 
Dixon et al., 2013). Yu et al. (1996) performed amino acid sequence comparison of p72 from a 
Ugandan strain from 1965, a Dominican Republic strain (DR-2), and two European strains 
(BA71V and E70) and found p72 to be highly conserved among them (Figure 1.2). This finding 
was supported by a subsequent study performed by de Villiers et al. (2010) in which mostly 
synonymous mutations were found in the nucleotide alignment of p72 from 11 ASFV isolates. 
Because of the antigenic stability of p72, it has been suggested that this protein would be a good 
candidate for use in the development of a diagnostic test for ASF (López-Otín et al., 1990). This 
study focuses on the N-terminal region of p72 due to this high conservation among isolates 
(Figure 1.3).  
Sequences of the variable genome regions of ASFV have been analyzed and used for 
genotyping different ASFV isolates. This is a valuable tool to distinguish between viruses that 
are causing outbreaks. Differentiation of the genomes by nucleotide sequence analysis can be 
accomplished by comparing the C-terminal end of p72 (Figure 1.4). This process has been used 
to identify 23 distinct ASFV genotypes (Achenbach et al., 2016; Bastos et al., 2003; Costard et 
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al., 2013). Complete viral discrimination between isolates can be achieved by combining the 
partial sequencing of p72, full sequencing of p54, and sequencing of the central variable region 
(CVR) of B602L (Atuhaire, Afayoa, Ochwo, Mwesigwa, Okuni, et al., 2013; Carmina Gallardo, 
Mwaengo, et al., 2009).  
 Antibodies to capsid protein p72 
Since there is no vaccine available for ASF, detection of antibodies to ASF is indicative 
that the animal had a previous infection with the virus. Pigs that survive natural infection 
produce antibodies to this virus between 7 and 10 days post infection. These antibodies persist 
for long periods, making them appropriate markers for diagnosis of the disease (Atuhaire, 
Afayoa, Ochwo, Mwesigwa, Mwiine, et al., 2013; Gallardo, Reis, et al., 2009). Protein p72 is 
one of the first viral proteins responsible for the induction of anti-ASFV antibodies after natural 
infection (Cubillos et al., 2013). It was demonstrated that antibodies to p72 neutralize infection 
of virulent ASFV isolates in Vero cell cultures and swine macrophages (Zsak et al., 1993) by 
preventing virus attachment (Gómez-Puertas et al., 1996) and in turn inhibiting virus replication. 
Along with the production of neutralizing antibodies to p72, the amino acid sequence of 
p72 is highly conserved among isolates making it a good candidate for serological diagnosis. 
Mapping the neutralization epitope, or epitopes, on the p72 protein using recombinant p72 
protein will be useful for structure-function analysis, the clarification of important biological 
processes, and for the development of serological assays (Cubillos et al., 2013; Yu et al., 1996).  
 Epitope mapping 
Epitope mapping is performed to identify the recognition sites of the antigen (epitopes) to 
which antibodies bind. Understanding the specific interaction between the antibodies and 
epitopes provides the foundation for the development of vaccines and serological-based assays 
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(Gershoni, Roitburd-Berman, Siman-Tov, Freund, & Weiss, 2012). B-Cell epitope mapping uses 
a series of overlapping synthetic peptides to identify linear antigenic determinants recognized by 
a particular antibody through an immunoassay, such as an ELISA. Using overlapping fragments 
ensures that epitopes are not missed by being cut at the fragment junctions (Heuzenroeder, 
Barton, Vanniasinkam, & Phumoonna, 2009). Epitope mapping makes it possible to identify and 
differentiate conformational and continuous epitopes. The structure of a conformational epitope 
depends on the intact conformation of the native protein. A continuous epitope is a linear peptide 
fragment of a protein that is able to bind to anti-protein antibodies (Sundberg, 2009; Van 
Regenmortel, 2009). The simplest way to identify desired epitopes is to isolate a monoclonal 
antibody that will bind to it. The “gold standard” for epitope mapping is the co-crystallization of 
the antigen-antibody complex followed by x-ray diffraction and analysis. A second approach to 
epitope mapping uses nuclear magnetic resonance (NMR) which gives a picture of the antigen-
antibody complex in solution. Other means of epitope mapping include computational docking, 
binding analyses, alanine scanning mutagenesis (ASM), and saturating mutagenesis (Gershoni et 
al., 2012).  
Previous studies have found that proteins p72, p54, and p30 of ASFV have immunogenic 
epitopes, although there is limited information available on the specific epitopes that anti-p72, 
p54, and p30 antibodies recognize (Neilan et al., 2004). One epitope in p54 was shown to be a 
DNA-binding domain (Escribano, Galindo, & Alonso, 2013)and a conformational-dependent 
neutralizing epitope was identified on p72 (Borca et al., 1994; Zsak et al., 1993).  
 Diagnostic tests 
Since ASF is a high-consequence pathogen, there are detrimental consequences of an 
ASFV-positive test result not only to the farmer but also to the region and country. Due to the 
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absence of a commercially available vaccine and the lack of a pen-side test for ASF, the correct 
diagnosis of the disease is the only method to help with outbreak surveillance and to completely 
eradicate ASFV from affected countries (Barderas et al., 2001; Perez et al., 2011). This results in 
a strong need for a highly sensitive and specific diagnostic test for the rapid detection of ASFV. 
It is essential to implement control measures in a timely manner to prevent virus spread and to 
differentiate ASF from the other swine diseases that have similar clinical symptoms (Alonso, 
2013; Oura et al., 2013).  
Diagnostic tests for ASF can be classified into two groups, those that detect the virus and 
those that detect anti-viral antibodies. The detection and identification of ASFV-specific 
antigens, viral DNA, or antibodies from samples is considered a positive diagnosis of ASFV 
(Oura et al., 2013). The OIE currently recommends multiple serological and virological 
diagnostic tests for the detection of the ASFV virus, its antigens, and its genome using the 
following: hemadsorption tests (HAD), polymerase chain reaction (PCR) assays, 
radioimmunoassays (RIA), fluorescent antibody tests (FAT), indirect fluorescent antibody (IFA), 
immunoblotting (IB), and enzyme-linked immunosorbent assays (ELISA). Samples that can be 
tested for ASFV include blood preserved in an anticoagulant, spleen, lymph nodes, liver, and 
tonsil (Crowther, Wardley, & Wilkinson, 1979; OIE, 2012; Oura et al., 2013). Other assays such 
as immunocytochemistry and in situ hybridization have been described in disease pathogenesis 
studies but are not ideal for routine diagnosis due to the need for specialized equipment and the 
difficulty in interpreting the results (Hutchings & Ferris, 2006; Mao, Javois, & Kent, 1994). 
OIE approved virological detection methods include assays such as PCR, FAT, and 
HAD. HAD is the “gold-standard” assay for ASFV diagnosis. It is a virus isolation technique 
that can be used to detect ASFV in peripheral blood leukocytes due to the ability of ASFV to 
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induce hemadsorption of the pig erythrocytes to the surface of infected monocytes or 
macrophages. A positive HAD test result can be obtained within 24 hours and is considered a 
conclusive diagnosis for ASFV. However, not all ASFV isolates are hemadsorbing and some 
will give negative results for a HAD test, resulting in the need for other diagnostic assays such as 
FAT. Other disadvantages for HAD tests include the requirement of primary cell cultures and the 
length of time of up to 6 days required to confirm a negative result.  
The “gold standard” test for the detection of the ASFV genome is PCR. The OIE 
recommends two validated PCR procedures, a conventional PCR and a real-time TaqMan® PCR. 
These methods use primer pairs and probes that target the coding region of the capsid protein 
p72. (OIE, 2012). There is also a loop-mediated isothermal amplification (LAMP) PCR assay 
that has been used for ASFV detection, although it is not recommended by the OIE (James et al., 
2010). Although PCR is a highly sensitive diagnostic method with the ability to detect virus in 
deteriorated samples, it generally requires expensive instruments for accurate thermocycling 
(OIE, 2012; Oura et al., 2013).  
Using rapid, sensitive, and specific serodiagnostic procedures could contribute to the 
eradication of ASFV in affected regions. Serological assays are the most commonly used 
diagnostic assays for detection of antibodies to ASFV in subacutely or chronically infected 
animals. However, they are not useful to test for ASFV in pigs with acute disease because these 
animals usually die prior to developing antibodies to ASFV. In addition, serological assays do 
not require expensive equipment and facilities and have a relatively low cost to run. In endemic 
regions, serological assays have been found useful for the detection of antibodies in samples 
from animals that survive infection since antibodies to ASFV persist for long periods of time. 
Serological assays approved by the OIE include IFA, IB, and ELISA. It has been found that 
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these tests are best when used in combination with other assays, especially when the techniques 
use crude antigens (Cubillos et al., 2013; Gallardo et al., 2015; OIE, 2012; Oura et al., 2013).  
The ELISA is used to detect ASF antibodies in pigs infected with low or moderately 
virulent viruses. The OIE-approved ELISAs for anti-ASFV antibody detection are based on the 
use of antigens obtained using live virus. This has several disadvantages including complications 
in achieving standardization of assays and risks associated with the handling of the virus as this 
requires the use of a biosafety level 3 (BSL-3) facility (Cubillos et al., 2013; Gallardo, Reis, et 
al., 2009; OIE, 2012). The ELISA is one of the most widely used techniques for the diagnosis of 
subacute and asymptomatic carriers of ASFV and was developed to assist in rapid diagnosis and 
to supplement the traditional HAD test for ASFV (Alcaraz, Diego, Pastor, & Escribano, 1990; 
Cubillos et al., 2013; Hutchings & Ferris, 2006). Although using an ELISA allows for the rapid 
screening of a large number of samples for the presence of virus or the antibody recognizing it, a 
disadvantage to this assay is that inconclusive results generally have to be confirmed by another 
assay (Alcaraz et al., 1990; Cubillos et al., 2013; Gallardo, Reis, et al., 2009; OIE, 2012). Using 
a standard ELISA that uses live virus for the production of ASFV antigens is ideal as a screening 
tool due to the high sensitivity of the assay. Disadvantages to the standard ELISA include the 
amount of false positive reactions obtained with field sera and the difficulty of standardizing the 
assay among laboratories. The use of recombinant proteins in place of conventional methods 
using live virus are alternative systems developed to resolve some of these issues. The use of 
recombinant proteins in diagnostic assays, such as the ELISA, offers a safe and reproducible 
alternative by providing a simpler interpretation of the test results, increasing assay specificity by 
reducing false positive reactions, avoiding using infectious virus, and allowing for the 
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standardization of antigen production (Barderas et al., 2001; Cubillos et al., 2013; Tabares et al., 
1981).  
IFA is used as a confirmatory test for inconclusive ELISA results for sera from endemic 
areas and for a positive ELISA result for sera from areas that are considered free of the disease. 
IB is a very specific assay that enables a more objective interpretation of results. It is used to 
confirm results with individual sera and is also used as an alternative confirmatory assay to IFA. 
These tests are based on the use of recombinant proteins which meet all biosecurity measures, 
providing accuracy and enabling a standardized diagnostic interpretation. IB is considered the 
“gold standard” assay recommended by the OIE as a confirmatory test for anti-ASFV antibody 
detection (Cubillos et al., 2013; Gallardo, Reis, et al., 2009; Muñoz-Moreno et al., 2015). 
Previously, protein p72 has been used in the development of ELISA-based diagnostic 
assays. Freije et al. (1993) developed an indirect ELISA test using recombinant p72 expressed in 
E.coli. Moreover, a study by Vidal et al. (1997) showed that a sandwich ELISA using 
monoclonal antibodies produced against p72 had high sensitivity and specificity against 
homologous sera. Cubillos et al. (2013) also showed that an indirect sandwich ELISA, based on 
ASFV recombinant protein p30, is an effective assay for the diagnosis of ASFV. It was 
recommended that another diagnostic test be used in combination with the ELISA due to the 
decreased sensitivity compared to the HAD test and the possibility that the ELISA may not 
detect low concentrations of the virus.  
In Europe, there are currently three ELISA kits commercially available for the detection 
of ASFV antibodies. One is an indirect ELISA by Svanova that targets protein p30. The other 
two assays use the major capsid protein p72 alone and in combination with other proteins as a 
target. The first is an IDvet multi-antigen indirect ELISA for the detection of monoclonal 
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antibodies against p30, pp62, and p72. The second is an Ingenasa blocking ELISA based on the 
use of monoclonal antibodies against p72  (Gallardo et al., 2015). There is also an Ingenasa 
antigen-capture assay based on the use of monoclonal antibodies to p72 for virus detection. 
 Blocking ELISA 
As mentioned previously, ASFV is a high consequence pathogen and an assay with high 
specificity is needed. A blocking ELISA is able to give this high specificity. The basic principle 
of this assay lies in the ability of the test sera to block the binding of a monoclonal antibody to 
the target antigen. It is important that the test sera and the monoclonal antibodies react to the 
same viral epitopes (Hasan et al., 2016). By epitope mapping p72, we will be able to determine 
which monoclonal antibody could best compete with known positive serum samples for antigen 
binding in order to create a better blocking ELISA. Shown in figure 1.5 is a blocking ELISA 
scheme. In an blocking ELISA, the plate is coated with the antigen and the sample is added. If 
antibodies are present in the sample, they will bind to the antigen. The monoclonal antibody is 
then added to the plate, and if the antibodies are bound to the antigen, they will block the binding 
of the monoclonal antibodies. In blocking ELISA with direct detection, the monoclonal antibody 
is already labeled with the enzyme. In our pilot assay, we did not have a labeled monoclonal 
antibody, therefore in order to visualize the results, an HRP-labeled anti-mouse monoclonal 
antibody was then added to the plate followed by the addition of the substrate. A light blue or 
clear well indicates a positive result, whereas a negative result will be a dark blue.  
Blocking ELISAs have been developed for the detection of Mycoplasma hyopneumonia, 
hepatitis E virus (HEV), and avian influenza virus (AIV), as well as other pathogens (Chen et al., 
2016; Henriques et al., 2016; Liu, 2014; Yang et al., 2016). Chen et al. (2016) compared a 
traditional ELISA to a blocking ELISA that tested for anti-HEV antibodies in pig serum. Their 
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results show the blocking ELISA seems to provide the same sensitivity and a higher specificity 
than the other assay. They found that blocking ELISAs based on the use of monoclonal 
antibodies could decrease the non-specific binding and help to improve the specificity of 
detection of antibodies in serum. Yang et al. (2016) and Henriques et al. (2016) compared 
different blocking ELISAs to the gold standard hemagglutination inhibition test (HI) for the 
detection of AIV and found a high correlation between the two assays and again, sensitivity and 
specificity were increased when compared to other ELISA assays. Furthermore, Liu et al. (2014) 
developed a blocking ELISA the for M. hyopneumoniae which had both high sensitivity and high 
specificity. A few advantages of using monoclonal antibodies for the detection of anti-ASFV 
antibodies includes a high specificity and an unlimited supply of a standardized reagent. Overall, 
using a blocking ELISA has the potential advantage of being a high throughput, rapid, sensitive, 
and specific method for the detection of anti-ASFV antibodies.  
 Alphavirus vectors 
The polyclonal serum used in this study was from pigs immunized with an alphavirus 
based vector expressing p72. Alphavirus-based vectors are single-cycle replication-deficient 
recombinant replicon particles (RP) that can express one or more protein of interest. The 
alphavirus genome is divided into two open reading frames (ORFs). The first ORF encodes the 
nonstructural proteins and the second ORF encodes the virus structural proteins, the capsid and 
envelope proteins. In the alphavirus-based vector, these proteins are replaced by the heterologous 
genes of interest. Then the replicon, together with the helper RNA coding for the capsid and 
envelope proteins, are co-electroporated into Vero cells. After 24 hours, the replicon particles are 
harvested. The use of alphaviruses in vaccine development is due to their ability to infect a broad 
range of animals without inducing symptoms; their low seroprevalence reduces interference with 
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immune response to the protein of interest. Advantages of using RPs include the ability to 
quickly obtain high titer virus preparations and not having the need for a helper virus to package 
the recombinant alphavirus RNAs. It has been shown that these vectors created good vaccines 
(Lundstrom, 2014; Rayner, Dryga, & Kamrud, 2002).  
 Purpose 
There is limited information on the immunogenic epitopes on the major capsid protein 
p72, and in the U.S. there are no commercially available tests for ASFV. The purpose of this 
study was to map the epitopes of ASFV major capsid protein p72 using polyclonal swine sera 
and a panel of monoclonal antibodies. The ultimate goal of this research is the development of a 
blocking ELISA for the detection of anti-ASFV antibodies.   
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 Tables and figures 
Figure 1.1 Virion structure of the African swine fever virus 
 
 
Figure 1.1 Virion structure of the African swine fever virus. ASFV is a multilayer virus with an icosahedral 
structure. The layers consist of a central nucleoid containing the DNA surrounded by a core shell. Outside this core 
shell is the inner envelope and surrounding the inner envelope is the capsid containing pE120R, pB438L, and major 
capsid protein p72. The virus obtains an outer envelope when budding through the cell membrane. ©2016. Mal 
Rooks Hoover, CMI.  
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Figure 1.2 Amino acid sequence alignment of the p72 whole protein 
 
Figure 1.2 Amino acid sequence alignment of the p72 whole protein. An amino acid alignment of the p72 whole protein from amino acid 1 to 646 of a sample 
of 8 genotypes. Dots indicate conservation of the amino acids in these locations of the sequence.  
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Figure 1.3 Amino acid sequence alignment of the N-terminus of the p72 protein 
 
Figure 1.3 Amino acid sequence alignment of the N-terminus of the p72 protein. An alignment of the N-terminal amino acid sequence alignment of the first 
345 amino acids of 8 different genotypes. Dots indicate the same amino acid. 
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Figure 1.4 Nucleotide sequence alignment of the C-terminus of the p72 protein 
 
Figure 1.4 Nucleotide sequence alignment of the C-terminus of the p72 protein. Shown on the left are isolates of 7 of the 23 different genotypes of ASFV. 
The C-terminus region of the p72 protein is the variable region that has been used to differentiate the 23 different genotypes. Dots indicate the same nucleotide. 
The red lines represent the forward and reverse primers used for genotyping. 
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Figure 1.5 Illustration of the blocking ELISA assay 
 
Figure 1.5 Illustration of the blocking ELISA assay. Antigen is bound to the plate. When the sample is added, if antibodies are present they will bind. When 
the monoclonal antibody is added, the antibodies from the serum will block the binding of the monoclonal antibody to the antigen. An HRP-labeled anti-mouse 
monoclonal antibody is then added to visualize the results. When the substrate is added, a positive sample will be light blue or clear, whereas a negative sample 
would be a strong blue. 
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Chapter 2 - Materials and Methods 
 Cloning, expression, and purification of recombinant ASFV p72 polypeptides 
 Cloning of overlapping fragments of the ASFV p72 protein 
The ASFV p72 protein, based on the BA71V strain, was divided into five overlapping 
fragments from amino acid (aa) 1 to 345: Fragment 1 (aa 1-100), Fragment 2 (aa 130 -250), 
Fragment 3 (aa 180-280), Fragment 4 (aa 250-345), and a fifth fragment referred to as P6 
(aa 83-171). Moreover, the p72 region between amino acids 180 and 250 and between amino 
acids 280 and 345 was divided further into Fragment A (aa 180-225), Fragment B (aa 205-250), 
Fragment C (aa 280-320), and Fragment D (aa 300-345) (Figure 2.1). The nucleotide sequences 
of all of the fragments were commercially synthesized. The fragments were cloned into the 
pCR2.1® TOPO® cloning vector (Invitrogen) following the manufacturer’s instructions. Briefly, 
an adenine nucleotide was added to the 3’ end of the fragments creating a 3’ A overhang. The 
reaction mixture used to create these overhangs consisted of 5 µl of DNA (10 ng/µl), 
1X polymerase buffer, 1 µm dATP, and 5 U Taq DNA polymerase (New England Biolabs, Inc.) 
in a total volume of 20 µl. This mixture was incubated at 72 ˚C for 15 minutes. The cloning 
reaction consisted of 4 µl of DNA with 3’ A overhangs, 1 µl of the pCR® 2.1-TOPO® vector, and 
1 µl of a salt solution. The reaction was incubated at room temperature for 5 minutes. E. coli 
chemically competent cells, either TOP10F’ (Invitrogen) or NEB 10-beta (New England Biolabs, 
Inc.), were then transformed with 2 µl of the product from the TOPO® cloning reaction. After a 
30-minute incubation on ice, the cells were heat-shocked at 42 ˚C for 30 seconds followed by an 
incubation period on ice for 5 minutes. Finally, 200 µl of super optimal broth with catabolite 
repression (SOC) medium (New England Biolabs, Inc.) was added to the cells, followed by a 
1-hour incubation at 37 ˚C in a shaking incubator. The cells were then inoculated onto 
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Luria-Bertani (LB) agar containing ampicillin and incubated overnight at 37 ˚C. Colonies were 
selected from the plates, transferred into LB media with ampicillin, and grown overnight at 
37 °C in a shaking incubator. The plasmid DNA was purified from the selected colonies using 
the PureYieldTM Miniprep Kit (Promega), following the manufacturer’s instructions. The 
plasmids were then analyzed for the presence of the target insert by double restriction enzyme 
digestion using SacII and EcoRI High-Fidelity restriction enzymes. For the restriction enzyme 
digestion reaction, 1 µg of purified plasmid DNA was mixed with 2 µl CutSmart Buffer (New 
England Biolabs, Inc.), 20 U of EcoRI-HF (New England Biolabs, Inc.), 20 U of SacII (New 
England Biolabs, Inc.) and nuclease-free water to make up a final volume of 20 µl. The reaction 
was then incubated for 1 hour at 37 ˚C followed by an enzyme inactivation step with incubation 
at 65 ˚C for 20 minutes. Products of the restriction enzyme digest were separated via agarose gel 
electrophoresis. This was accomplished by preparing 1% agarose gels containing ethidium 
bromide, loading the digestion products into the wells of the gels, and running the gel for 30 
minutes at 100 volts. The fragments were visualized by examining the gel under UV light. 
One of the clones containing the target band was used for subcloning into the pHUE 
expression vector (Figure 2.2a). The plasmid containing the target insert was subjected to double 
restriction digestion as described above, the target band was gel purified using Wizard® SV Gel 
and PCR Clean-Up system (Promega), following the manufacturer’s instructions. Purified DNA 
was then ligated into the pHUE expression vector by mixing 1 µl of 10X T4 DNA Ligase buffer, 
50 ng of vector DNA, purified DNA at 1:3 ratio (vector:DNA), 1 µl of T4 DNA Ligase and 
nuclease-free water up to 20 µl. The reaction mixture was incubated at room temperature for 
30 minutes and transformed into TOP10F’ or NEB 10-beta E. coli competent cells (New 
England Biolabs, Inc.), as described above. The clones were screened, as described above. One 
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clone containing pHUE with the target band was selected and the plasmid was used to transform 
BL21 (DE3) E. coli chemically competent cells (New England Biolabs, Inc.), following 
manufacturer’s instructions. Briefly, 20 µl of BL21 (DE3) chemically competent cells were 
transformed with 2 µl of the pHUE plasmid. The cells were incubated on ice for 30 minutes, then 
heat shocked for 30 seconds at 42 ˚C, followed by incubation on ice for 5 minutes. SOC medium 
(200 µl) was added to the cells followed by incubation in a shaking incubator at 37 ˚C for 1 hour. 
The cells were then added to 7 ml LB media with ampicillin (Fisher Scientific), returned to the 
shaking incubator, and incubated overnight at 37 ˚C.  The resulting culture was then used for 
protein expression and a bacterial stock was prepared and stored at -80 ˚C for future use. 
 Protein expression 
For the purpose of recombinant protein expression, BL21(DE3) E. coli cells, containing 
the pHUE plasmid with one of the p72 fragments, were grown in LB media at 37 ºC until the 
optical density (OD600) reached between 0.4 and 0.6. Protein expression was induced by the 
addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM. 
After addition of IPTG, the bacterial cells were grown for an additional 4 hours and then 
harvested by centrifugation 4000 x g for 10 minutes. Aliquots of 1 ml were taken hourly starting 
before the addition of IPTG. The aliquots were pelleted and suspended in 100 µl of SDS sample 
buffer (sodium dodecyl sulfate with Tris-HCl pH 6.8, glycerol, β-mercaptoethanol, 
ethylenediaminetetraacetic acid (EDTA) and bromophenol blue) for analysis by SDS-PAGE. 
Prior to gel electrophoresis, the aliquots collecting during the protein expression were boiled for 
5 minutes before loading into the gel. Electrophoresis was performed at 150 V for approximately 
45 minutes. The gel was washed with warm double distilled water three times for 1 minute each 
and was stained for 10 minutes using Coomassie blue staining (SimplyBlueTM SafeStain by 
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Novex). After staining, the gel was washed again using warm double distilled water. A picture of 
the gel was acquired using the UVP GelDoc-ItTM Imaging System. 
 Purification under native conditions 
Proteins were purified using a PrepEase® Histidine-tagged Protein Purification Kit 
(USB). The pellet obtained from the protein expression protocol was suspended in 1X lysis, 
equilibration and wash (LEW) buffer (50 mM sodium dihydrogen phosphate and 300 mM 
sodium chloride, pH 8.0), with 10 µl/ml of EDTA-free protease inhibitor cocktail (PIC) 
(THERMO scientific), and 1 mg/ml of lysozyme. After incubation on ice for 30 minutes, 
sonication was performed using the Model 3000 Ultrasonic Homogenizer (Biologics, Inc.) for 
3 minutes at 40% power. The bacterial lysate was then centrifuged at 10,000 x g for 30 minutes. 
The supernatant was filtered with a 0.45-µm PVDF syringe filter (Fisher) to eliminate any 
insoluble material. Next, gravity flow, affinity chromatography was performed by the addition of 
the filtered lysate to a Ni-IDA mini column to capture the 6X Histidine-tagged polypeptides. 
After three 2-ml washes with 1X LEW buffer, the protein was eluted three times  with volumes 
of  1.5 ml, 1.5 ml, and 2 ml  in 1X elution buffer (50 mM sodium dihydrogen phosphate, 
300 mM sodium chloride and 250 mM Imidazole, pH 8.0). The elutions were stored at 4 ˚C until 
used in western blots and ELISAs. The purification was confirmed by SDS-PAGE and western 
blot with anti-histidine tag monoclonal antibody.  
 Protein purification using detergent  
 This protocol used the detergent Sarkosyl (sodium lauroyl sarcosinate) in CAPS 
(3-[Cyclohexylamino]-1-propanesulfonic acid) buffer (CAPS/Sarkosyl). The protocol for protein 
purification using CAPS/Sarkosyl was the same as the “native” protocol through the initial 
centrifugation step. The pellet post-centrifugation was suspended in 0.5 M CAPS/0.3% Sarkosyl 
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buffer (pH 8.0) at a concentration of 10-15 mg of pellet per milliliter of buffer. The suspended 
pellet was subjected to four freeze-thaw cycles with temperatures at -80 ºC and 37 ºC, 
respectively. The bacterial lysate was then centrifuged at 10,000 x g for 30 minutes at 4 ºC. The 
supernatant was filtered with a 0.22-µm filter and purified using Ni-IDA column. The 
purification using the Ni-IDA columns was as described above with the exception of the wash 
and elution buffers that were used. The wash buffer was 1X LEW with 0.5 M CAPS/0.3% 
Sarkosyl, while the elution buffer was 1X Elution buffer with 0.5 M CAPS/0.3% Sarkosyl.  
 Purification under denaturing conditions 
The protocol for purification under denaturing conditions was the same as the “native” 
protocol through the initial centrifugation step. After centrifugation of the bacterial lysate, the 
supernatant was discarded and the pellets were suspended in 1X LEW buffer with 8M urea. The 
suspended pellets were incubated on ice for 30 minutes followed by sonication for 3 minutes at 
40% power and then centrifugation at 10,000 x g for 30 minutes. Ni-IDA column purification 
was carried out the same as previously described in the “native” protocol with the exception of 
using 1X LEW and 1X elution buffers combined with 8M urea. 
 Polyclonal swine serum 
The polyclonal swine serum samples were obtained from pigs immunized with an 
alphavirus-based replicon particle expressing the extracellular domain of the HA protein (based 
on the E75 strain) together with the p72 whole protein (based on the BA71V strain).  
 Monoclonal antibodies 
The panel of 29 monoclonal antibodies were produced by our collaborators at the Foreign 
Animal Disease Diagnostic Laboratory (FADDL) at Plum Island Animal Disease Center 
(PIADC). The monoclonal antibodies were produced against a truncated p72 protein (from 
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amino acids 20 to 303) based on a current ASFV strain, Georgia/07, and expressed in 
baculovirus. This protein was used for mouse immunizations and also as an antigen in the 
indirect ELISA for screening the monoclonal antibodies. The monoclonal antibodies were 
screened at FADDL using indirect ELISA and immunofluorescence assay (IFA). 
 Synthesized oligopeptides 
Overlapping 15-mers, coupled with ovalbumin, were commercially synthesized by 
21st Century Biochemicals (Table 2.1). These oligomers were made corresponding to the areas of 
reactivity of the monoclonal antibodies. 
 Indirect ELISA 
A 96-well flat-bottom plate (Costar) was coated with 100 µl of protein diluted to 4 µg/ml 
in carbonate coating buffer (CCB) and incubated for one hour at 37 ºC. The plate was washed 
three times with 0.05% Tween 20 in PBS (PBS-T) and then blocked by adding 100 µl of 10% 
goat serum in PBS (PBS-GS) to each well and incubated for one hour at 37 ºC.  The plate was 
frozen at -20 ˚C if the assay was to be done at a later time. After washing the plate three times 
with PBS-T, the primary antibodies were added.  Substances used as the primary antibody source 
were polyclonal swine serum from two pigs immunized with RP-sHA-p72 (Pig #5 and Pig #9, 
Day 57), a negative-control serum sample, and a panel of monoclonal antibodies. Two-fold serial 
dilutions in PBS-GS were done across the 96-well plate for each of these then the plate was 
incubated at 37 ˚C for 1 hour. The plate was washed three times with PBS-T before the 
secondary antibody was added. The secondary antibodies used were goat anti-swine IgG 
conjugated to horse radish peroxidase (HRP) (ICN Biomedicals Inc.), diluted 1:2000 in PBS-GS, 
for the polyclonal sera and goat anti-mouse IgG conjugated to HRP (ICN Biomedicals Inc.), 
diluted 1:500 in PBS-GS, for the monoclonal antibodies. The plate was washed three times with 
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PBS-T then 100 µl of ABTS® Microwell Peroxidase Substrate colorimetric reagent was added to 
visualize the reaction. After incubation at room temperature for 20 minutes, 100 µl of 1% SDS in 
double-distilled water was added to stop the reaction. Absorbance values were read at 405 nm 
and 650 nm. The absorbance of the sample was obtained by subtracting absorbance reading 
A650 from absorbance reading A405. Fine mapping was then performed by indirect ELISA 
using overlapping 15-mers coupled with ovalbumin as the antigen and following the above 
protocol. 
 Western blotting 
Western blots were performed using purified elutions from each of the five fragments and 
the p72 whole protein. The protein fragments were separated in a 12% SDS-PAGE gel by 
electrophoresis done at 150 V for 45 minutes. The proteins were then blotted into a 0.2 µm 
PVDF membrane (Amersham)  as follows: the SDS-PAGE gel was rinsed three times for 5 
minutes each in PBS-T on a shaking platform; the membrane was activated by submerging it in 
100% methanol followed by rinsing it in double-distilled water for 10 minutes on a shaking 
platform; and the gel, filter papers and PVDF membrane were soaked for 20 minutes in 
1X transfer buffer (glycine, tris base, SDS, double-distilled water and methanol). The blot 
apparatus was assembled and the electrophoretic transfer was done using a Mini Trans-Blot® 
Electrophoretic Transfer Cell (BIO-RAD, Hercules, CA) following the manufacturer’s 
instructions. After transfer, the membrane was blocked using 5% non-fat dry milk in PBS 
(NFDM) or protein-free buffer and incubated overnight at 4 ˚C. Following the blocking step, the 
membrane was washed three times with PBS-T, the first time for 15 minutes followed by two 
additional wash steps for 5 minutes each. The primary antibody was then added to the membrane 
and incubated for 1 hour at room temperature. The primary antibody sources used were 
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anti-histidine monoclonal antibody, diluted 1:1000 in NFDM; polyclonal swine sera from two 
pigs immunized with RP-sHA-p72 at day 0 and day 57, diluted 1:300 in protein-free blocking 
buffer (G-Biosciences); and 29 monoclonal antibodies, diluted 1:100 each in NFDM. The 
incubation was followed by three washes with PBS-T as described above. An HRP-labeled 
secondary antibody was then added and the membrane was incubated for 1 hour at room 
temperature on a shaking platform. The secondary antibodies used were goat anti-mouse IgG 
conjugated to HRP that was diluted 1:500 in NFDM when mouse monoclonal antibodies were 
used as the primary antibody and goat anti-swine IgG conjugated to HRP that was diluted 1:3000 
in protein-free blocking buffer when polyclonal swine serum was used as the primary antibody. 
The reaction was visualized by using the CN/DAB Substrate Kit (Thermo Scientific Pierce) by 
adding the substrate to the membrane and incubating it on a shaking platform for 5 to 10 minutes 
at room temperature until color developed. The reaction was stopped by rinsing the membrane 
with double-distilled water. A picture of the membrane was acquired using the UVP GelDoc-ItTM  
Imaging System. 
 Determining monoclonal antibody half-maximum values 
Five anti-p72 reactive monoclonal antibodies were further tested to determine their half-
maximum values, the concentration at which 50% of the monoclonal antibody reacts with its 
antigen. This was accomplished by performing indirect ELISAs using the ASFV p72 whole 
protein as the antigen. The protocol described above was again used but with the following 
modifications: two-fold dilutions of the selected p72 monoclonal antibodies were made  starting 
from the 1:200 dilution; and the secondary antibody was goat anti-mouse IgG conjugated to HRP 
(ICN Biomedicals, Inc.) at a dilution of 1:4000. 
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 Blocking ELISA with indirect detection 
A 96-well flat-bottom plate (Costar) was coated with 100 µl of ASFV p72 whole protein 
diluted to 4 µg/ml in CCB, leaving the last row without protein, and then incubated for 1 hour at 
37 ºC. The plate was washed three times with PBS-T and then blocked by adding 100 µl of 10% 
PBS-GS to each well. The plate was incubated for 1 hour at 37 ˚C.  Following incubation, the 
plate was again washed three times with PBS-T. Polyclonal swine serum from two pigs 
immunized with RP-sHA-p72 (Pig #5 and Pig #9, Day 57) and a negative-control serum were 
added undiluted to the first well of each column, doubling dilutions were performed using 
PBS-GS, and the plate was incubated at 37 ˚C for 1 hour. The plate was washed three times with 
PBS-T and then the monoclonal antibodies were added. The monoclonal antibodies were used at 
dilutions corresponding to their half-maximum absorbance values then the plate was incubated at 
37 ˚C for 30 minutes. The plate was washed three times with PBS-T after which the secondary 
antibody, goat anti-mouse IgG conjugated to HRP (ICN Biomedicals, Inc.), was added at a 
dilution of 1:4000 in PBS-GS and incubated at 37 ˚C for one hour. The plate was washed three 
times with PBS-T then 100 µl of ABTS® Microwell Peroxidase Substrate colorimetric reagent 
was added to each well to visualize the reaction. After incubation at room temperature for 
20 minutes, 100 µl of 1% SDS in double-distilled water was added to the wells to stop the 
reaction. The absorbance of the sample was obtained by subtracting measurements read at 
405 nm and 650 nm.  
 
38 
 Tables and figures 
Figure 2.1 ASFV p72 overlapping fragment scheme 
 
Figure 2.1 ASFV p72 overlapping fragment scheme. ASFV p72 (based on BA71V) from amino acid 1 to 345 was divided into fragments 1, P6, 2, 3, and 4. 
The region from amino acid 180 to 250 was divided further into Fragment A (FrA) and Fragment B (FrB) and the region from amino acid 280 to 345 was divided 
further into Fragment C (FrC) and Fragment D (FrD). Sixteen overlapping oligopeptides are shown below from amino acid 100 to 171 and amino acid 250 to 
303.  
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Figure 2.2 The pHUE expression vector 
 
Figure 2.2 The pHUE expression vector. A. Plasmid map of the pHUE expression vector showing the T7 
promoter, ubiquitin, and restriction enzyme recognition sites (Catanzariti, Soboleva, Jans, Board, & Baker, 2004). 
The protein sequences were inserted between restriction enzyme recognition sites for SacII and EcoRI. B. A 
histidine-ubiquitin-ASFV fusion protein. 
  
A.  
B.  
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Table 2.1 Oligopeptides and their corresponding amino acids 
Oligopeptide Amino Acids 
I 100-114 
II 105-119 
III 110-124 
IV 115-130 
V 130-144 
VI 135-149 
VII 140-154 
VIII 145-159 
IX 150-165 
X 156-171 
XI 250-264 
XII 255-269 
XIII 260-274 
XIV 265-280 
XV 280-294 
XVI 290-303 
Table 2.1 Oligopeptides and their corresponding amino acids. Sixteen overlapping 15-mers coupled with 
ovalbumin used for the fine mapping of ASFV major capsid protein p72. 
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Chapter 3 - Results 
 Production of ASFV p72 overlapping fragments in Escherichia coli 
Fragments were initially cloned into the pCR® 2.1-TOPO® cloning vector (Invitrogen) 
and inserted into NEB 10-beta cells. Agarose gel electrophoresis of the PCR products was 
performed. Subsequent analysis of the gels revealed a single band of the correct size for all of the 
ASFV p72 fragments (data not shown). The rationale for using pCR® 2.1-TOPO® as a shuttle 
vector include the following: the creation of 5’-A and 3’-T overhangs for the direct ligation of 
the PCR products obtained from amplification with Taq polymerase, the speed and efficiency of 
ligation, the presence of EcoRI and SacII recognition sites flanking the PCR product insertion 
site for easy scanning of clones, inclusion of both kanamycin and ampicillin resistance genes for 
selection in E. coli, and the ability to perform blue/white colony screening. Inserts were then 
digested from the pCR® 2.1 vector with the SacII and EcoRI enzymes and inserted in frame into 
the SacII and EcoRI sites of the pHUE vector. These two sites were selected due to the 
nucleotide sequence of the fragments being devoid of the recognition sequences for the SacII and 
EcoRI restriction enzymes.  
 The pHUE E. coli expression vector was utilized because the products of expression 
with this vector include a 6X histidine tag and ubiquitin. The 6X histidine tag allows for simple 
affinity column purification and the fusion of cloned peptides to ubiquitin increases the bacterial 
expression and solubility of the peptides. Successful cloning of the fragments into the pHUE 
expression vector is shown by the agarose gel electrophoresis of the double restriction enzymatic 
digestion reactions with the restriction enzymes SacII and EcoRI which reveals a single band of 
the correct size for all p72 fragments (Figure 3.1). 
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To express fusion proteins of ubiquitin with the p72 fragments, the pHUE vector 
containing the fragments was initially transformed into BL21 (DE3) E. coli competent cells 
(Invitrogen). This cell line was selected for its capability to express proteins from the T7 
promoter efficiently. In order to optimize protein expression, aliquots were taken immediately 
prior to induction with IPTG as well as every hour thereafter for a total of 4 hours. After 4 hours 
of incubation with IPTG, SDS-PAGE analysis showed peak expression of all products with each 
fragment and the p72 whole protein being of the correct size (Figure 3.2). Fragments 2, 3, P6, A, 
B, C, and D were purified using the manufacturer’s protocol for native conditions. Not all 
fragments were soluble under native conditions which led to the conclusion that these proteins 
were forming insoluble inclusion bodies inside the E. coli bacterial cells. Fragment 4 was 
purified using CAPS/Sarkosyl, and by using the strong denaturant urea, Fragment 1 and the p72 
whole protein were purified using the protocol for purification under denaturing conditions. 
Overall, transformation, expression, and purification of each fragment and the p72 whole protein 
resulted in a band of the predicted molecular weight, along with other proteins co-purified with 
the target band (Figure 3.3).  Each fragment and the p72 whole protein reacted positively when 
tested on a western blot against the anti-histidine monoclonal antibody. This antibody recognizes 
the 6X histidine tag and confirmed the purification of the ASFV p72 proteins (Figure 3.4). 
Monoclonal antibody screening 
The monoclonal antibodies were produced and screened at FADDL by ELISA using 
baculovirus-expressed p72 as well as by IFA on ASFV Lisbon-infected cells. As shown in 
table 3.5, all of the 29 monoclonal antibodies recognized the p72 protein by ELISA. On the other 
hand, only 6 of the 29 monoclonal antibodies recognized the native form of the protein in the 
ASFV-infected cells. Furthermore, the isotype of each monoclonal antibody was determined and 
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the majority of them were of the IgG1 kappa (IgG1κ) isotype, although four were a mixture of 
two different clones. In addition, in our laboratory, all 29 of the monoclonal antibodies were 
tested against the p72 protein expressed in E. coli. Of these, 27 out of 29 had positive results. 
The remaining two monoclonal antibodies were not considered further in this study (Table 3.5). 
 Mapping of ASFV p72 epitopes using polyclonal serum and monoclonal 
antibodies 
Polyclonal serum samples from two pigs, Pig #5 and Pig #9, immunized with the 
RP-sHA-p72 construct were reacted against the ASFV p72 whole protein and the p72 fragments 
on both ELISA (Figure 3.5) and western blot (Figure 3.6). The polyclonal sera reacted to the p72 
regions between amino acids 1 and 83 and between amino acids 250 and 345. The reactivity of 
the polyclonal sera for both ELISA and western blot is summarized in Table 3.1. A panel of 
29 monoclonal antibodies produced against a truncated p72 protein, from amino acid 20 to 303, 
was also reacted on ELISA (Figure 3.7) and western blot (Figure 3.8) against the p72 whole 
protein and fragments. As stated previously, we did not consider the 2 monoclonal antibodies 
that did not react with the p72 whole protein for further mapping. The other 27 monoclonal 
antibodies tested for mapping reacted to the p72 regions between amino acid 100 to 170 and 
amino acid 180 to 303 (Table 3.2). The reactivity of the monoclonal antibodies can be divided 
into five distinct groupings: Group 1, from amino acid 100 to 130; Group 2, from amino acid 130 
to 180; Group 3, from amino acid 180 to 250; Group 4, from amino acid 250 to 280; and 
Group 5, from amino acid 180 to 303 (Table 3.3). Five monoclonal antibodies (7C5, 9G6, 9G11, 
5B10, and 81) reacted with two different protein regions. Three monoclonal antibodies (7C5, 
9G6, and 9G11) reacted by ELISA and western blot with the region between amino acid 100 and 
130 and cross-reacted to the region between amino acid 280 and 303 by ELISA. Monoclonal 
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antibody 5B10 reacted with the epitope between amino acids 160 and 165 and cross-reacted on 
ELISA with the p72 region between amino acids 280 to 303. Also, monoclonal antibody 81 
reacted to the regions between amino acids 130 and 171 as well as between amino acids 250 and 
280.  
Based on the identification of those monoclonal antibody reactive regions, fine mapping 
was performed using overlapping 15-mers coupled with ovalbumin. The oligomers were reacted 
against the monoclonal antibodies by ELISA, and six linear epitopes were identified (Table 3.4). 
One of the monoclonal antibodies that reacted to the oligomers, monoclonal antibody 81, 
recognized two different epitopes (amino acid 165 to 170 and amino acid 250 to 255). Figure 3.9 
illustrates a summary scheme of the reactivity of the polyclonal sera against the p72 fragments 
together with the reactivity of the monoclonal antibodies against the p72 fragments and 
oligomers.  
 Blocking ELISA with indirect detection 
Of the 27 anti-p72 reactive monoclonal antibodies tested, five were chosen for the 
development of a blocking ELISA. The monoclonal antibodies were chosen based on two 
characteristics: their recognition of the native form of the protein as shown by IFA on ASFV-
infected Vero cells, and their recognition of a p72 conserved area as shown by the comparison of 
the N-terminal amino acid sequences of a representative sample of eight isolates belonging to 
different genotypes (Figure 3.10). For the development of the blocking assay, polyclonal sera 
from pigs #5 and #9 and the selected monoclonal antibodies were used. The monoclonal 
antibodies were used at a dilution corresponding to their absorbance half-maximum as 
determined by indirect ELISA (Figure 3.11), while the polyclonal sera were used undiluted and 
then two-fold serially diluted. Two out of five monoclonal antibodies tested (monoclonal 
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antibodies 85 and 23) in the blocking ELISA produced clear results together with the polyclonal 
sera used undiluted (Figure 3.12). The mean was calculated for each monoclonal antibody using 
the absorbances of three wells without serum. To determine the cutoffs for positive and negative 
results, two times the standard deviation was added or subtracted from the mean. An absorbance 
above the negative cutoff was considered a negative result and an absorbance below the positive 
cutoff was considered a positive result. The points that exist between these cutoffs require further 
testing. Monoclonal antibody 23 is one of the monoclonal antibodies with a mixed isotype; it will 
need to be subcloned before it can be used further in the development of the blocking assay. 
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 Tables and figures 
Figure 3.1 Double restriction enzyme digestion of the pHUE plasmid containing p72 
fragment inserts 
       
     
 
  
Figure 3.1 Double restriction enzyme digestion of the pHUE plasmid containing p72 fragment inserts. 
Successful cloning of ASFV p72 fragments. A. Fragment 1 (Fr1) is 300 base pairs (bp); fragment P6 is 264 bp; 
fragment 2 (Fr2) is 360 bp; fragment 3 (Fr3) is 300 bp; and fragment 4 (Fr4) is 285 bp. B. Fragment A (FrA) is 148 
bp; fragment B (FrB) is 145 bp; fragment C (FrC) is 133 bp; and fragment D (FrD) is 145 bp.  
  
A. 
B. 
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Figure 3.2 Protein expression 
     
 
 
   
Figure 3.2 Protein expression. The ladder is the standard molecular marker, Kaleidoscope (Bio-Rad). 0h is before 
induction with IPTG, 4h is 4 hours after induction with IPTG. A. Expressions of ASFV p72 fragments 1-4, P6, and 
p72 whole protein. B. Expressions of ASFV p72 fragments A-D.  
  
A. 
B. 
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Figure 3.3 Protein purification 
 
Figure 3.3 Protein purification. The ladder is the standard molecular marker, Kaleidoscope (Bio-Rad). The first 
elution of the purifications of ASFV p72 fragments 1-4, fragment P6, fragments A-D, and p72 whole protein. A 
band of the correct molecular weight is seen for each of the fragments and whole protein as indicated by the arrows.  
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Figure 3.4 p72 Western blot with anti-histidine monoclonal antibody 
 
     
 
      
Figure 3.4 p72 Western blot with anti-histidine monoclonal antibody. The ladder is the standard molecular 
marker, Kaleidoscope (Bio-Rad) A.. Fragments 1, P6, 2, 3, 4, and the p72 whole protein were tested on western blot 
against anti-histidine monoclonal antibody. Fragment 1 (Fr1), P6, and fragment 4 (Fr4) are 20 kDa. Fragment 2 
(Fr2) is 23 kDa. Fragment 3 (Fr3) is 21 kDa. The p72 whole protein is 75 kDa. B. Fragments A and B were tested on 
western blot against an anti-histidine monoclonal antibody along with fragments 2 and 3 as a positive control. 
Fragment A (FrA) and fragment B (FrB) are 15 kDa. Fragments C and D were tested on western blot against an anti-
histidine monoclonal antibody along with fragment 4 for a positive control. Fragment C (FrC) and fragment D (FrD) 
are both 15 kDa and fragment 4 (Fr4) is 20 kDa.   
A. 
B. 
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Figure 3.5 p72 ELISA with polyclonal sera at 1:160 dilution 
 
Figure 3.5 p72 ELISA with polyclonal sera at 1:160 dilution. The ASFV p72 fragments and p72 whole protein 
were tested on an ELISA against the polyclonal swine sera from pigs #5 and #9 at  day 0 (negative control sera) and 
at day 57.  
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Figure 3.6 p72 Western blot with polyclonal swine sera 
 
Figure 3.6 p72 Western blot with polyclonal swine sera: The ladder is the standard molecular marker, 
Kaleidoscope (Bio-Rad). Only the p72 reactive fragments are shown in the picture.  Pig# 5 and pig# 9 are the 
sources of the polyclonal sera at day 57 used in the assay. Arrows indicate the bands corresponding to the p72 
fragments and p72 whole protein. 
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 Table 3.1 Polyclonal epitope mapping summary table for western blot and ELISA  
 
 
Polyclonal 
Serum 
Antigen: E. coli expressed recombinant proteins 
p72-Fr1 
(aa 1-100) 
p72-P6 
(aa 83-171) 
p72-Fr2 
(aa 130-250) 
p72-Fr3 
(aa 180-280) 
p72-Fr4 
(aa 250-345) 
p72 whole 
protein 
(aa 1-646) 
ELISA WB ELISA WB ELISA WB ELISA WB ELISA WB ELISA WB 
Pig #5 + - - - - - + + + + + + 
Pig #9 + + - - - - + + + + + + 
 
 
 
Antigen: E. coli expressed recombinant proteins 
Polyclonal  
Serum 
p72-FrA 
(aa 180-225) 
p72-FrB 
(aa 205-250) 
p72-FrC 
(aa 280-320) 
p72-FrD 
(aa 300-345) 
 ELISA WB ELISA WB ELISA WB ELISA WB 
Pig #5 - - - - - - - - 
Pig #9 - - - - + + - - 
Table 3.1 Polyclonal epitope mapping summary table for western blot and ELISA. A. Fragments 1, P6, 2, 3, 4, 
and whole protein. B. Fragments A, B, C, and D. For both figures A and B, a reaction is indicated with (+) and no 
reaction is indicated with (-).  
 
A. 
B. 
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Figure 3.7 p72 ELISA with monoclonal antibodies and negative control serum at 1:16 dilution 
 
Figure 3.7 p72 ELISA with monoclonal antibodies and negative control serum at 1:16 dilution. CD-2v_46 is the negative control monoclonal antibody that 
was used.  
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Figure 3.8 Western blot of p72 with monoclonal antibodies 
 
 
 
 
 
Figure 3.8 Western blot of p72 with monoclonal antibodies: As described in Materials and Methods, the ASFV 
p72 fragments were tested against a panel of monoclonal antibodies. In figures A-E (C, D, and E are on following 
page), the ladder is the standard molecular marker, Kaleidoscope (Bio-Rad). A. Monoclonal antibodies 2B6, 5G1, 
8F7-3, 85, and 89. B. Monoclonal antibodies 9G6, 23, 7C5, 4A4, and 61. (Continued on the following page) 
 
 
 
 
 
 
A. 
B. 
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Figure 3.8. Western blot of p72 with monoclonal antibodies (continued) 
 
 
 
 
 
Figure 3.8 Western blot of p72 with monoclonal antibodies (continued): C. Monoclonal antibodies 9G11, 8C11, 
7H4, 94, and 54. D. Monoclonal antibodies 10C7, 34, 8H8, 81, and 58. E. Monoclonal antibodies 6F9-10, 8H2-1, 
65-1, 6H9-1, and 5B10.   
D. 
E. 
C. 
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Table 3.2 Monoclonal antibody epitope mapping summary for western blot and ELISA 
p72 mAbs 
Antigen: E.coli expressed recombinant proteins 
p72-P6 
(aa 83-171) 
p72-Fr2 
(aa 130-250) 
p72-Fr3 
(aa 180-280) 
p72-Fr4 
(aa 250-345) 
p72 whole protein 
(aa 1-646) 
ELISA WB ELISA WB ELISA WB ELISA WB ELISA WB 
10C7 - - + + + + - - + + 
23 - - - - - - + + + + 
2B6 - - - - - - + + + + 
34 + + + - - - - - + + 
4 +    - - - - - - - +                                     -
4A4 - - - - - - + + + + 
54 + + + + - - - - + + 
58 + + + + - - - - + + 
5B10 + + + + - - + - - + 
5G1 + + + + - - - - + + 
61 + + + + - - - - + + 
7C5 + + - - - - + - - + 
7H4 + + + + - - - - + + 
81 + + + + + - + + + + 
85 + + + + - - - - + + 
89 + + + + - - - - + + 
8B12 - - - - - - + - + - 
8C11 + + + + - - - - + + 
8H8 + + + + - - - - + - 
94 + + - - - - - - + + 
9G11 + + - - - - + - - + 
9G6 + + - - - - + - - + 
65-3 - - - - + + + + + + 
6F9-10 + + + + - - - - + + 
6H9-1 - - - - + + + + + + 
8F7-3 - - - - - - + + + + 
8H2-1 + + + + - - - - + + 
 
Table 3.2 Monoclonal antibody epitope mapping summary for western blot and ELISA. A positive reaction is 
indicated with (+) and no reaction is indicated with (-).  
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Table 3.3 Monoclonal antibody groupings 
Group 1 
(amino acid 100-130) 
4 9G11 
7C5 9G6 
94  
Group 2 
(amino acid 130-171) 
7H4 54 
58 5B10 
5G1 61 
61 81 
85 89 
8C11 8H8 
6F9-10 34 
8H2-1  
Group 3 
(amino acid 180-250) 
10C7  
Group 4 
(amino acid 250-280) 
65-3 6H9-1 
81  
Group 5 
(amino acid 280-345) 
4A4 8B12 
8F7-3 23 
2B6 7C5 
9G11 9G6 
Table 3.3 Monoclonal antibody groupings.  
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Table 3.4 Oligomer reactivity with anti-p72 reactive monoclonal antibodies 
 Antigen: E.coli expressed 
recombinant proteins 
Antigen: synthesized oligomers 
p72 mAbs Mapping Location Epitope recognized 
10C7 180-250 N.D. 
23 280-345 280-289 
2B6 280-345 280-289 
34 130-171 160-165 
4 100-130 (ELISA only) No reactivity 
4A4 250-345 295-303 
54 130-171 160-165 
58 130-171 160-165 
5B10 130-171;  
280-345 (ELISA only) 
160-165 (No reactivity with overlapping 
oligomers between aa 280 and 303) 
5G1 130-171 N.D. 
61 130-171 160-165 
7C5 100-130;  
280-345 (ELISA only) 
No reactivity 
7H4 130-171 160-165 
81 130-171; 
260-280 (ELISA only); 
280-345 (WB only) 
250-255 and 160-165 
85 130-171 160-165 
89 130-171 160-165 
8B12 250-345 (ELISA only) 295-303 
8C11 280-345 (ELISA only) 160-165 
8H8 130-171 165-171 
94 100-130 No reactivity 
9G11 100-130; 
280-345 (ELISA only) 
No reactivity 
9G6 100-130; 
280-345 (ELISA only) 
No reactivity 
65-3 250-280 275-280 
6F9-10 130-171 160-165 
6H9-1 250-280 275-280 
8F7-3 280-345 280-289 
8H2-1 130-171 160-165 
Table 3.4 Oligomer reactivity with anti-p72 reactive monoclonal antibodies. The anti-p72 monoclonal 
antibodies reacted with E. coli expressed recombinant proteins mapping region compared with the epitopes 
recognized by monoclonal antibodies when reacted to synthetic oligomers. N.D. = Not done.  
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Figure 3.9 Epitope mapping summary scheme  
 
Figure 3.9 Epitope mapping summary scheme. The blue line, from amino acid 20 to amino acid 303, is the ASFV p72 fragment (based on the Georgia/07 
strain) used for mouse immunization for the monoclonal antibodies. Numbers 1 to 345 represent amino acid positions of ASFV p72 (based on BA71V). 
Polyclonal sera reactivity to the p72 fragments is shown as the red asterisks and monoclonal antibody reactivity to the p72 fragments is shown in black. 
Oligopeptides are the black lines illustrated below with reactivity to the monoclonal antibodies in purple. Monoclonal antibodies selected for further testing in the 
blocking ELISA are circled in blue. 
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Table 3.5 Monoclonal antibody screening results 
 
mAbs 
 
 
Isotype 
Baculovirus-
Expressed p72 
Lisbon-Infected 
Vero cells 
E.coli-Expressed  
p72 whole protein  
ELISA IFA ELISA WB 
10C7 IgA-κ + - + + 
23 IgG1-κ /λ + + + + 
2B6 IgG1-κ /λ + - + + 
34 IgG1-κ + - + + 
4 IgG1-κ + - + - 
4A4 IgG1-κ + + + + 
54 IgG1-κ + - + + 
58 IgG1-κ + - + + 
5B10 IgG1/IgG3-κ + - - + 
5G1 IgG1-κ + - + + 
61 IgG1-κ + - + + 
6B1 IgG1-κ + - - - 
6C7 No Reactivity + - - - 
7C5 IgG1-κ + - - + 
7H4 IgG1-κ + - + + 
81 IgG1-κ + - + + 
85 IgG1-κ + + + + 
89 IgG1-κ + - + + 
8B12 IgG1/IgM-k + - + - 
8C11 IgG1-κ + - + + 
8H8 IgG1-κ + - + - 
94 IgG1-κ + - + + 
9G11 IgG1-κ + - - + 
9G6 IgG1-κ + - - + 
65-3 IgG1-κ + + + + 
6F9-10 IgG1-κ + - + + 
9H9-1 IgG1-κ + + + + 
8F7-3 IgG1-κ + + + + 
Table 3.5 Monoclonal antibody screening results. Monoclonal antibodies were screened by ELISA using 
baculovirus-expressed p72 and screened by IFA in ASFV-infected cells. Furthermore, the isotype of each 
monoclonal antibody was determined and tested against the protein based on BA71V expressed in E.coli.  
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Figure 3.10 Monoclonal antibody reactivity to the N-terminal amino acid sequence alignment of the p72 protein 
 
Figure 3.10 Monoclonal antibody reactivity to the N-terminal amino acid sequence alignment of p72. Conservation of the reactive epitopes to the 
monoclonal antibodies selected for further development of a blocking ELISA (85, 65-3, 6H9-1, 8F7-3, and 23). Monoclonal antibody 85 reacted to the epitope 
from amino acid 160 to 165, monoclonal antibodies 65-3 and 6H9-1 reacted to the epitope from amino acid 275 to 280, and monoclonal antibodies 8F7-3 and 23 
reacted to the epitope from amino acid 280 to 290.  
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Figure 3.11 Determination of monoclonal antibody half-maximum values 
 
Figure 3.11 Determination of monoclonal antibody half-maximum values. The monoclonal antibodies used for 
the blocking ELISA were used corresponding to their half-maximum absorbance as determined by indirect ELISA.  
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Figure 3.12 Blocking ELISA with indirect detection 
      
         
         
Figure 3.12 Blocking ELISA with indirect detection: A. Monoclonal antibody 85 reactivity against two positive 
serum samples, Pig #5 and Pig #9, and a negative control serum. B. Monoclonal antibody 23 against two positive 
serum samples, Pig #5 and Pig #9, and a negative control serum. Negative control serum reactivity is in blue, Pig #5 
reactivity is in red, and Pig #9 reactivity is shown in green on both graphs. Positive and negative cutoffs were 
determined by the addition or subtraction of two standard deviations from the mean of three wells with no serum.  
  
A. 
B. 
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Chapter 4 - Discussion and Conclusion 
Since there are no commercially available diagnostic assays for ASFV in the United 
States and limited information on the immunogenic epitopes on the major capsid protein p72, 
this project focused on the epitope mapping of p72 for the development of a blocking ELISA.  
We were successful in expressing the p72 whole protein and the overlapping 
polypeptides as p72-ubiquitin fusion proteins. The ubiquitin fused to the proteins served to 
increase the solubility and expression of the proteins (Catanzariti et al., 2004). Although we used 
an E. coli expression plasmid containing ubiquitin, the p72 whole protein, fragment 1, and 
fragment 4 remained insoluble. The results of the p72 expression are in accordance with a 
previous study where the p72 whole protein was expressed in E. coli and found to be insoluble 
(Freije et al., 1993). It was found that 8M urea was needed for the purification of fragment 1 and 
the p72 whole protein. The insolubility of fragment 1 could possibly be explained by the 
presence of multiple hydrophobic amino acid residues within the sequence. The formation of 
insoluble inclusion bodies can be the result of the over-expression of recombinant proteins in 
E. coli (Singh & Panda, 2005). The solublilization and recovery from the inclusion bodies is 
complex and protein specific but can be accomplished by using a detergent such as Sarkosyl or 
the strong denaturant urea. The successful use of Sarkosyl for purification of many proteins that 
form insoluble inclusion bodies has previously been reported (Frankel, Sohn, & Leinwand, 1991; 
Singh & Panda, 2005). This method was used for the purification of fragment 4.  
Through epitope mapping, this study has identified multiple areas of antigenic reactivity 
on the ASFV major capsid protein, p72. The amino acid alignment comparison between BA71V 
and Georgia/07 shows only one amino acid difference at position 126 in the first 345 amino acids 
of p72. The single amino acid difference did not have any effect on the reactivity of the 
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monoclonal antibodies to p72. This is in accordance with previous comparisons of isolates which 
demonstrated that ASFV p72 is highly conserved among them (de Villiers et al., 2010; Yu et al., 
1996). 
Zsak et al. (1993) identified a highly conserved neutralizing epitope and Borca et al. 
(1994) determined that this epitope, which is located between amino acid 393 and 442, is 
conformational. After testing the 27 monoclonal antibodies for the fine mapping of p72, we 
identified six linear epitopes upstream of the previously identified conformational epitope. These 
six epitopes were determined to be linear due to their ability to recognize very small epitopes 
when tested on western blot. Of the 27 monoclonal antibodies tested, five monoclonal antibodies 
were found to have reactivity with multiple regions on p72. Although the double reactivity of 
monoclonal antibody 5B10 can be explained by the fact that it was shown to have a mixed 
isotype, it is unclear why the other monoclonal antibodies reacted to two different regions.  
There is a definite need for a reliable diagnostic assay for ASFV. This is largely due to 
the fact that no commercial vaccine for ASFV is currently available. The rapid serodiagnosis of 
ASFV could contribute to the complete eradication of the disease in certain regions affected by 
the virus and could also help prevent spread of the disease into countries that are currently 
unaffected by it. The use of monoclonal antibodies specific to p72 allows for the development of 
a sensitive, specific, and reproducible blocking ELISA and helps to ensure the highly specific 
nature of the test system. Also, because recombinant protein p72 is used in the assay, there is no 
need to work with live virus which eliminates the requirement for performing the assay in a 
BSL-3 facility. During the development of a blocking ELISA, five of the 27 monoclonal 
antibodies tested were selected based on their ability to recognize the native form of the whole 
protein as well as a conserved area within the sequence. The results of the pilot blocking ELISAs 
66 
with the selected anti-p72 monoclonal antibodies and sera from pigs immunized with defective 
alphavirus particles expressing sHA-p72 show two promising candidates out of the five that were 
selected, monoclonal antibodies 85 and 23. These monoclonal antibodies will be used for further 
evaluation using sera from ASFV-infected pigs. However, anti-p72 monoclonal antibody 23 is 
not a pure monoclonal antibody as it was determined to have a mixed isotype of IgG1-k/λ. This 
antibody will need to be subcloned prior to being used further in the development of a blocking 
ELISA. 
ASFV is a high-consequence pathogen and therefore, the development of a tool for the 
rapid and reliable detection of ASFV is needed. This research allows for future development of 
such an assay as well as for other research endeavors using the antigenic regions of major capsid 
protein p72.  
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